AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6083688 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 107
Study 29179562 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional support during hospitalization
Number of subjects: 243
Study 29179562 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 243
Study 30541098 — intervention group
Group type: EXPERIMENTAL
Intervention: HC/HF diet (carbohydrate-rich meals until 1330 and fat-rich meals between 1630 and 2200)
Number of subjects: 29
Study 30541098 — intervention group
Group type: COMPARATOR
Intervention: HF/HC diet (inverse sequence of meals)
Number of subjects: 29
Study 26804606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program administered by volunteers for eight weeks, three times each week
Number of subjects: 36
Study 26804606 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with standard 'friendly visits'
Number of subjects: 36
Study 24890747 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour magnesium sulfate therapy
Number of subjects: 120
Study 24890747 — intervention group
Group type: COMPARATOR
Intervention: 24-hour magnesium sulfate therapy
Number of subjects: 120
Study 22803759 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-based instruction
Number of subjects: 53
Study 22803759 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 53
Study 20823169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated wrist splint
Number of subjects: 96
Study 20823169 — intervention group
Group type: COMPARATOR
Intervention: Short arm cast
Number of subjects: 96
Study 18294504 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-magnification endoscopy (EME)
Number of subjects: 380
Study 18294504 — intervention group
Group type: COMPARATOR
Intervention: Conventional magnification endoscopy (CME) / magnification chromoendoscopy (MCE)
Number of subjects: 380
Study 15919798 — intervention group
Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala-Ala) monoclonal antibody
Number of subjects: 0
Study 12843392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 12843392 — intervention group
Group type: EXPERIMENTAL
Intervention: N-methyl-D-aspartate-receptor blocker
Number of subjects: 0
Study 12843392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12843392 — intervention group
Group type: COMPARATOR
Intervention: Left index finger (no drug)
Number of subjects: 0
Study 10655977 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg CuSO4
Number of subjects: 24
Study 10655977 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg Cu-glycine chelate (CuGC)
Number of subjects: 24
Study 10655977 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg Cu-glycine chelate (CuGC)
Number of subjects: 24
Study 10655977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8666715 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 54
Study 8666715 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diazepam
Number of subjects: 54
Study 8666715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2065695 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 0
Study 2065695 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 0
Study 2065695 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 0
Study 2065695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3884577 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 8
Study 3884577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 8
Study 3884577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31443886 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltimore City Drug Treatment Court (BCDTC)
Number of subjects: 235
Study 31443886 — intervention group
Group type: COMPARATOR
Intervention: Traditional adjudication
Number of subjects: 235
Study 30153453 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing-distance interval training (100–200–300–400–500 m), twice a week for six weeks
Number of subjects: 40
Study 30153453 — intervention group
Group type: COMPARATOR
Intervention: Decreasing-distance interval training (500–400–300–200–100 m), twice a week for six weeks
Number of subjects: 40
Study 28229646 — intervention group
Group type: COMPARATOR
Intervention: PT (Physical Training)
Number of subjects: 34
Study 28229646 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + NT (Physical Training + Nutritional Therapy)
Number of subjects: 34
Study 24680961 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan lactate wafer containing tizanidine HCl
Number of subjects: 0
Study 24680961 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablet Sirdalud(®)
Number of subjects: 0
Study 22985205 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine-only
Number of subjects: 81
Study 22985205 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + fluoxetine
Number of subjects: 81
Study 22985205 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + placebo
Number of subjects: 81
Study 20030470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg with tapentadol IR 80 mg
Number of subjects: 62
Study 20030470 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg with tapentadol IR 80 mg
Number of subjects: 62
Study 20030470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 325 mg with tapentadol IR 80 mg
Number of subjects: 62
Study 20030470 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol IR 80 mg alone
Number of subjects: 62
Study 21978966 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidant VITALITY 2 with Rhythm ID
Number of subjects: 1962
Study 21978966 — intervention group
Group type: COMPARATOR
Intervention: Medtronic pulse generators using Enhanced PR Logic or Wavelet discrimination algorithms
Number of subjects: 1962
Study 15949725 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min)
Number of subjects: 18
Study 15949725 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (50 nmol/min)
Number of subjects: 18
Study 15949725 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min) + L-NMMA (2 micromol/min)
Number of subjects: 18
Study 15949725 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (50 nmol/min) + L-NMMA (4 micromol/min)
Number of subjects: 18
Study 15949725 — intervention group
Group type: COMPARATOR
Intervention: BQ-123
Number of subjects: 18
Study 15949725 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ET-1 levels
Number of subjects: 18
Study 14612933 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (50,000 IU per day) for six months
Number of subjects: 81
Study 14612933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 14612933 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol
Number of subjects: 81
Study 9728850 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1 L/min
Number of subjects: 90
Study 9728850 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at 1 L/min
Number of subjects: 90
Study 9728850 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion with desflurane
Number of subjects: 90
Study 9728850 — intervention group
Group type: COMPARATOR
Intervention: Esmolol infusion with isoflurane
Number of subjects: 90
Study 7662503 — intervention group
Group type: EXPERIMENTAL
Intervention: HK subjects
Number of subjects: 30
Study 7662503 — intervention group
Group type: EXPERIMENTAL
Intervention: HK + FSS subjects
Number of subjects: 30
Study 7662503 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 2914739 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive antiarrhythmic treatment
Number of subjects: 0
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiordazine (THI) at single daily doses not exceeding 375 mg/day for 6 months
Number of subjects: 35
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (PIM) at single oral doses not exceeding 16 mg/day
Number of subjects: 35
Study 1112170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 35
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drug groups (THI and PIM)
Number of subjects: 35
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS scale
Number of subjects: 35
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Social adjustment ratings
Number of subjects: 35
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects with THI
Number of subjects: 35
Study 1112170 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects with PIM
Number of subjects: 35
Study 31492912 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (proton pump inhibitors, clarithromycin, and amoxicillin)
Number of subjects: 0
Study 31492912 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA plus BSEF (Bacillus subtilis and Enterococcus faecium)
Number of subjects: 0
Study 31492912 — intervention group
Group type: COMPARATOR
Intervention: PCA (control group)
Number of subjects: 0
Study 31492912 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA plus BSEF (TP group)
Number of subjects: 0
Study 28292885 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal endurance training combined with strength training (E+S)
Number of subjects: 19
Study 28292885 — intervention group
Group type: COMPARATOR
Intervention: Normal endurance training (E)
Number of subjects: 19
Study 26133726 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at SP 6, SP 9, GB 39, and ST 36 for 30 minutes
Number of subjects: 72
Study 26133726 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA) at SP 6, SP 9, GB 39, and ST 36 for 30 minutes
Number of subjects: 72
Study 26133726 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) relaxed for 30 minutes
Number of subjects: 72
Study 22890616 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention for weight control
Number of subjects: 167
Study 20965780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125 to 0.75 mg once daily)
Number of subjects: 402
Study 20965780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 18705691 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 224
Study 18705691 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 224
Study 16804427 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV; FluMist)
Number of subjects: 197
Study 16804427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 12709753 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 95
Study 12709753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 12709753 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Placebo
Number of subjects: 95
Study 11101476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat diet (600 g/d)
Number of subjects: 5
Study 11101476 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet (0 g/d)
Number of subjects: 5
Study 11101476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine serum albumin or casein added to fecal batch cultures
Number of subjects: 5
Study 8833212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical clodronate therapy (200 mg IV infusion every 3 weeks)
Number of subjects: 235
Study 8833212 — intervention group
Group type: COMPARATOR
Intervention: Control group (183 postmenopausal osteoporotic patients)
Number of subjects: 235
Study 1317089 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified soft jelly capsule containing nonoxynol-9 (DF-486)
Number of subjects: 40
Study 2859931 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg qid (mean dose 340 mg/day)
Number of subjects: 12
Study 2859931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30442986 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted bitterness of caffeine
Number of subjects: 438870
Study 30442986 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PROP perception
Number of subjects: 438870
Study 30442986 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quinine perception
Number of subjects: 438870
Study 30442986 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher caffeine perception
Number of subjects: 438870
Study 30442986 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher bitterness perception of tea
Number of subjects: 438870
Study 27340881 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (Nuvelle)
Number of subjects: 59
Study 27340881 — intervention group
Group type: COMPARATOR
Intervention: COCP (Microgynon 30)
Number of subjects: 59
Study 27340881 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59
Study 24825416 — intervention group
Group type: EXPERIMENTAL
Intervention: LY1 dosing algorithm
Number of subjects: 0
Study 24825416 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2 dosing algorithm
Number of subjects: 0
Study 24825416 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL) dosing algorithm
Number of subjects: 0
Study 22301439 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+) T-cell-guided therapy interruption (TI)
Number of subjects: 106
Study 22301439 — intervention group
Group type: COMPARATOR
Intervention: therapy continuation
Number of subjects: 106
Study 21301680 — intervention group
Group type: EXPERIMENTAL
Intervention: GP reply letter sent from a community mental health service
Number of subjects: 39
Study 21301680 — intervention group
Group type: COMPARATOR
Intervention: No GP reply letter
Number of subjects: 39
Study 17651961 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined olive oil (ROO) meal
Number of subjects: 28
Study 17651961 — intervention group
Group type: COMPARATOR
Intervention: High‐palmitic sunflower oil (HPSO) meal
Number of subjects: 28
Study 17651961 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial response
Number of subjects: 28
Study 15653962 — intervention group
Group type: EXPERIMENTAL
Intervention: INR 3.0 to 4.5
Number of subjects: 2735
Study 15653962 — intervention group
Group type: EXPERIMENTAL
Intervention: INR 2.5 to 4.0
Number of subjects: 2735
Study 15653962 — intervention group
Group type: EXPERIMENTAL
Intervention: INR 2.0 to 3.5
Number of subjects: 2735
Study 15653962 — intervention group
Group type: EXPERIMENTAL
Intervention: All INR strata
Number of subjects: 2735
Study 11994612 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews with health care providers regarding breast implant concerns
Number of subjects: 820
Study 11994612 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for information
Number of subjects: 820
Study 11994612 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings expressed by women
Number of subjects: 820
Study 11994612 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for accurate information from health care professionals
Number of subjects: 820
Study 10201101 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential observing response procedure; no specific dosage or duration mentioned.
Number of subjects: 3
Study 10201101 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition; no specific dosage or duration mentioned.
Number of subjects: 3
Study 7768234 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low intensity aerobic training (treadmill, 30 min, 3-6 times a week for 9 months)
Number of subjects: 30
Study 7768234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 30
Study 7768234 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (after 1 month in 5 patients)
Number of subjects: 30
Study 2324998 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal public self disclosure
Number of subjects: 0
Study 2324998 — intervention group
Group type: EXPERIMENTAL
Intervention: Arithmetic task
Number of subjects: 0
Study 2324998 — intervention group
Group type: EXPERIMENTAL
Intervention: Self disclosure task with low perceived social approval
Number of subjects: 0
Study 218717 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin 60 mg/m2 (T60)
Number of subjects: 55
Study 218717 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin 20 mg/m2 (T20)
Number of subjects: 55
Study 218717 — intervention group
Group type: COMPARATOR
Intervention: No thymosin (P)
Number of subjects: 55
Study 31468177 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved needle
Number of subjects: 69
Study 31468177 — intervention group
Group type: COMPARATOR
Intervention: Non-curved needle
Number of subjects: 69
Study 27650432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) including psychoeducation, breathing training, and cognitive restructuring over a 6-month period
Number of subjects: 61
Study 27650432 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical services (Control)
Number of subjects: 61
Study 27294597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling intervention
Number of subjects: 0
Study 27294597 — intervention group
Group type: COMPARATOR
Intervention: Control group (low risk for OSA)
Number of subjects: 0
Study 24415784 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily for 24 weeks
Number of subjects: 147
Study 24415784 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 147
Study 23094055 — intervention group
Group type: EXPERIMENTAL
Intervention: VS411 (didanosine 200 mg/HC 900 mg once-daily)
Number of subjects: 58
Study 23094055 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 58
Study 19488605 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Positive Airway Pressure (EPAP) at 7 cm H2O for 30 minutes
Number of subjects: 40
Study 19488605 — intervention group
Group type: COMPARATOR
Intervention: T-tube for 30 minutes
Number of subjects: 40
Study 17255270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 236
Study 17255270 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense chemotherapy (DDCT)
Number of subjects: 236
Study 16327486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 151
Study 16327486 — intervention group
Group type: COMPARATOR
Intervention: End-to-side pancreaticojejunostomy (PJ)
Number of subjects: 151
Study 12431240 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CHOP (-like) chemotherapy
Number of subjects: 0
Study 12431240 — intervention group
Group type: COMPARATOR
Intervention: Standard local practice (SLP) chemotherapy
Number of subjects: 0
Study 12431240 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients receiving SLP chemotherapy
Number of subjects: 0
Study 9213327 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide followed by preoperative docetaxel
Number of subjects: 283
Study 9213327 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide followed by postoperative docetaxel
Number of subjects: 283
Study 9213327 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin/cyclophosphamide with tamoxifen (control group)
Number of subjects: 283
Study 10134424 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared or integrated care for asthma
Number of subjects: 0
Study 10134424 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient care for asthma
Number of subjects: 0
Study 3312824 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine (8 to 10 mmol/L) in a blood cardioplegic solution
Number of subjects: 78
Study 3312824 — intervention group
Group type: COMPARATOR
Intervention: Standard blood cardioplegia
Number of subjects: 78
Study 29433145 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quintile of cord blood magnesium levels
Number of subjects: 1254
Study 30440270 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly Selected Wavelet Transform (RSWT) feature extraction and machine learning scheme for ECG delineation
Number of subjects: 0
Study 27085828 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant TKI therapy prior to CN (Group 2)
Number of subjects: 61
Study 27085828 — intervention group
Group type: COMPARATOR
Intervention: Primary CN followed by adjuvant TKI (Group 1)
Number of subjects: 61
Study 27085828 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary TKI alone (Group 3)
Number of subjects: 61
Study 27085828 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant TKI therapy (Group 2)
Number of subjects: 61
Study 25352508 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day HBPM protocol with measurements taken before morning micturition and in the afternoon (BM+AM)
Number of subjects: 158
Study 25352508 — intervention group
Group type: COMPARATOR
Intervention: 3-day HBPM protocol with post-morning-micturition and evening measurements (PM+EM)
Number of subjects: 158
Study 25352508 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day HBPM protocol
Number of subjects: 158
Study 22672586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d. added to ongoing open-label metformin (1000 or 1700 mg/day) for 24 weeks
Number of subjects: 395
Study 22672586 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ongoing open-label metformin (1000 or 1700 mg/day) for 24 weeks
Number of subjects: 395
Study 20493644 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interventions (BMI)
Number of subjects: 1336
Study 20493644 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual plus assessment (TAU+)
Number of subjects: 1336
Study 18797098 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical pulpotomy (35 teeth)
Number of subjects: 70
Study 18797098 — intervention group
Group type: COMPARATOR
Intervention: Formocresol pulpotomy (35 teeth)
Number of subjects: 70
Study 16059696 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBI
Number of subjects: 120
Study 16059696 — intervention group
Group type: EXPERIMENTAL
Intervention: TGN
Number of subjects: 120